(Q43774214)

26 November 2017

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials (English)

1 reference

26 November 2017

1 reference

Coney P

1

1 reference

26 November 2017

Washenik K

2

1 reference

26 November 2017

Langley RG

3

1 reference

26 November 2017

DiGiovanna JJ

4

1 reference

26 November 2017

Harrison DD

5

1 reference

26 November 2017

1 June 2001

1 reference

26 November 2017

1 reference

26 November 2017

63

1 reference

26 November 2017

6

1 reference

26 November 2017

297-302

1 reference

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

A Placebo-Controlled Double-Blind Crossover Investigation of the Side Effects Attributed to Oral Contraceptives*†*Presented at the Twenty-Seventh Annual Meeting of the American Fertility Society, New Orleans, Louisiana, March 25–27, 1971.†This

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

A comparative analysis of three different dose combinations of oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Weight gain in adolescent and young adult oral contraceptive users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Factors associated with short-term oral contraceptive discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

Clinician/patient interaction: communicating the benefits and risks of oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900208-6

10.1016/S0010-7824(01)00208-6

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference